Low intensity bridging may be best path to CAR T in adult ALLJune 1, 2019ALLLeukemia, Myelodysplasia, Transplantation
NGS comparable to FC for minimal residual disease assessmentMay 17, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
Tagraxofusp produces high response rate in BPDCNApril 24, 2019Leukemia, Myelodysplasia, TransplantationALL
Creating CAR T-cell therapies for T-cell malignanciesApril 16, 2019ALLLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Whole-genome sequencing demonstrates clinical relevanceApril 4, 2019AMLALLLeukemia, Myelodysplasia, Transplantation
MRD status at transplant predicts outcomes in ALL patientsMarch 14, 2019TransplantationALLLeukemia, Myelodysplasia, Transplantation
Haplo-HSCT bests chemotherapy for MRD-positive adult ALLMarch 13, 2019TransplantationALLLeukemia, Myelodysplasia, Transplantation
EC approves dasatinib plus chemo for kids with Ph+ ALLFebruary 11, 2019ALLPediatricsLeukemia, Myelodysplasia, Transplantation
PD-1 blockade plus CD19 CAR T boosts CAR T-cell persistenceFebruary 8, 2019ALLPediatricsLeukemia, Myelodysplasia, TransplantationTransplantation
Immunotherapy’s cardiac effects require early monitoring, managementFebruary 5, 2019ThrombosisLeukemia, Myelodysplasia, TransplantationALL
EC approves blinatumomab for MRD-positive BCP-ALLJanuary 25, 2019Leukemia, Myelodysplasia, TransplantationALL
FDA approves dasatinib for kids with Ph+ ALLJanuary 3, 2019Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyALL
Group proposes new grading systems for CRS, neurotoxicityJanuary 3, 2019Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaTransplantationALLNon-Hodgkin LymphomaAggressive Lymphomas
FDA approves calaspargase pegol-mknl for ALLDecember 24, 2018Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyALL
